San Francisco-based Qardio announces the launch of its fully remote end-to-end patient monitoring (RPM) service, which now includes cardiac arrhythmia analysis. Specifically, QardioDirect—its service for RPM—offers ambulatory cardiac monitoring to help diagnose atrial fibrillation, along with a range of other arrhythmias. Multiple short duration recordings can identify symptomatic and asymptomatic periods of cardiac activity. Then, as a more detailed analysis is needed—a full 24-48 hours—Holter analysis can be prescribed with rapid turnaround and reporting.
Qardio’s Holter monitor, QardioCore, is a patient-friendly device, according to the company. No skin preparation is needed. There are no gels, patches, or wires, which provide optimum patient comfort. This ensures high patient compliance and high diagnostic yields, which results in better patient outcomes, they add.
“Thanks to Qardio, we’ve been able to catch at least three patients who had heart arrhythmias. We were then able to send them immediately to a cardiologist,” says QardioDirect-user, George Fahnbulleh, from Gold Canyon Internal Medicine in Arizona. “The benefits of using QardioDirect are phenomenal.”
QardioDirect with ECG is the future of RPM, according to Qardio officials, and they say they’re proud to be at the forefront. “Qardio’s history of innovation continues as we launch RPM and Holter analysis services in a single, unified workflow,” says Qardio’s co-founder, Rosario Iannella. “QardioDirect is the only platform that enables practitioners to remotely identify changes in the patient baselines across multiple key vital signs and also diagnose a wide range of cardiac arrhythmias.”
Featured image: The QardioCore ambulatory ECG from Qardio
